checkAd

     109  0 Kommentare Bristol Myers Squibb Releases 2023 Environmental, Social and Governance Report Demonstrating Progress and Setting New Long-Term Goals - Seite 2

    • Made clinical trials more accessible to underrepresented groups, by embedding 58% of U.S. clinical trial sites in racially and ethnically diverse metro areas of the U.S., surpassing its initial goal of 25% set in 2020.
    • Worked to ensure research efforts better reflect patient populations, BMS exceeded goals for racially diverse clinical trial participants in the U.S. with 26% vs. target 20%; achieved 23% ethnically diverse patients, exceeding goal of 18%. Moving forward, BMS is focused on increasing the percentage of racially and ethnically diverse patients enrolled in clinical trials globally across key indications, including Lupus, Multiple Myeloma, Pulmonary Fibrosis and Alzheimer's Disease.

    Inclusive Global Workforce: Inclusion, Diversity and Culture

    • Sustained workforce representation: 47.4% of employees at the executive level are female.
    • Increased community engagement: BMS employees logged nearly 9,000 volunteer hours worldwide in 2023 to help improve the communities where they live and work.

    Sustaining Our Planet and Improving Health: Climate and Environment

    Anzeige 
    Handeln Sie Ihre Einschätzung zu Bristol-Myers Squibb!
    Long
    40,11€
    Basispreis
    0,39
    Ask
    × 10,41
    Hebel
    Short
    50,44€
    Basispreis
    0,59
    Ask
    × 6,88
    Hebel
    Präsentiert von

    Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie bei Klick auf das Disclaimer Dokument. Beachten Sie auch die weiteren Hinweise zu dieser Werbung.

    • Advanced climate action goals: In 2023, BMS published its inaugural Task Force on Climate-related Financial Disclosures (TCFD) Report and submitted science-based targets to the Science Based Targets initiative for external validation.
    • Increased renewable energy footprint: In November 2023, BMS announced a second 15-year virtual power purchase agreement (VPPA) with National Grid Renewables for 145 megawatts of solar at the Texas-based Blevins Solar Project in line with its 2030 goal of 100% purchased electricity from renewable sources.

    Ethics and Conduct: Operating with Integrity

    • Incorporated new ESG metrics into the executive compensation program, measuring achievement against environmental and social goals and better aligning executive bonuses with company strategy.
    • Advanced data privacy and cybersecurity efforts: In 2023, BMS developed the Next-Generation Privacy Program focused on ensuring broad global market coverage, accountability for decision rights and privacy ownership, and data inventories, which will be implemented in early 2024.
    • Established Principles for Responsible Artificial Intelligence: BMS defined and published ethical standards and practical requirements for the development, deployment, and use of artificial intelligence.

    Lesen Sie auch

    Click here for BMS' full 2023 ESG Report.

    Seite 2 von 3
    Der Analyst erwartet ein Kursziel von 46,32$, was eine Steigerung von +5,00% zum aktuellen Kurs entspricht. Mit diesen Produkten können Sie die Kurserwartungen des Analysten übertreffen.
    Übernehmen
    Für Ihre Einstellungen haben wir keine weiteren passenden Produkte gefunden.
    Bitte verändern Sie Kursziel, Zeitraum oder Emittent.
    Alternativ können Sie auch unsere Derivate-Suchen verwenden
    Knock-Out-Suche | Optionsschein-Suche | Zertifikate-Suche
    WerbungDisclaimer


    Diskutieren Sie über die enthaltenen Werte


    Accesswire
    0 Follower
    Autor folgen
    Mehr anzeigen
    We’re a newswire service standout and fast becoming an industry disruptor. We provide regional, national and global news to thousands of clients around the world. We’re also leading the way in social engagement, targeting and analytics.
    Mehr anzeigen

    Verfasst von Accesswire
    Bristol Myers Squibb Releases 2023 Environmental, Social and Governance Report Demonstrating Progress and Setting New Long-Term Goals - Seite 2 Company builds on its strengths to advance patient access, product innovation, culture and inclusion and diversityPRINCETON, NJ / ACCESSWIRE / April 2, 2024 / Bristol Myers Squibb CompanyOriginally published on Bristol Myers Squibb News & …

    Schreibe Deinen Kommentar

    Disclaimer